FindTrial
Sign In

Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer

A Prospective Observational Study on Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/04/024780
Enrollment
250
Registered
2020-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Anil Tibdewal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All consecutive patients with histologically proven lung cancer with radiologically confirmed bone metastases and planned for radiotherapy at TMH. 2.All patients planned for radiotherapy at Tata Memorial Hospital.

Exclusion criteria

Exclusion criteria: 1.Age 2.Patients who are not willing to come for follow up after EBRT completion. 3.Patients with spinal cord compression at presentation. 4.Patients requiring reirradiation at the previously treated site.

Design outcomes

Primary

MeasureTime frame
To evaluate objective pain response at 2 and 4 weeks (+/-3 days) in lung cancer patients treated with radiotherapy for bone metastasesTimepoint: 2 and 4 weeks—

Secondary

MeasureTime frame
To evaluate objective pain response of assessable patients at 3 and 6 months Time to reirradiation for the same site To evaluate the prognostic factors affecting the treatment response To subjectively assess the quality of life using EORTC QOL and BM 22 Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Amiya Agrawal

Tata Memorial Hospital

aniltibdewal@gmail.com022-24177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026